Takehiko Ohzeki a , Keiichi Hanaki a , Hiroko Motozumi a , Hiroko Ohtahara b , Nobuo Ishitani a , Hirofumi Urashima a , Toshinori Tsukuda a , Kazuo Shiraki a , Shigekazu Sasaki b , Hirotoshi Nakamura b , Hiroo Imura b
03 December 2008
The relation between thyroid-stimulating hormone (TSH) and triiodothyronine (T<sub>3</sub>) was evaluated in a girl with the selective pituitary type of thyroid hormone resistance for more than 7 years to clarify whether bromocriptine was an effective treatment or not. Levels of T3 (before: 2.44 ± 0.64 nmol/l, mean ± SD) and TSH (4.81 ± 2.52 mU/1) were significantly decreased during therapy (T<sub>3</sub>: 2.15 ± 0.44 nmol/l; TSH: 1.59 ± 0.78 mU/l). T<sub>3</sub> × TSH, calculated as one of the indices of pituitary resistance, on bromocriptine therapy (3.229 ± 1.255 mU/l × nmol/l) was significantly (p < 0.005) smaller than the product before the administration (11.298 ± 5.891 mU/l × nmol/l). The results suggest that bromocriptine should be one of the agents initially considered for the treatment of pituitary resistance to thyroid hormone.